Cefmatilen: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 18:56, 8 August 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:W← Previous edit		Latest revision as of 22:16, 29 January 2023 edit undoEntranced98 (talk \| contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,416 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper
(12 intermediate revisions by 11 users not shown)
Line 1:		Line 1:
			{{Short description\|Chemical compound}}
	{{drugbox
			{{Drugbox
⚫	\| ~~UNII_Ref~~ = {{~~fdacite~~\|correct\|~~FDA~~}}
		⚫	\| verifiedrevid = 443726531
⚫	\| UNII = T750UM24H8
		⚫	\| IUPAC_name = (6''R'',7''R'')-7-{amino}-8-oxo-3-{sulfanyl}-5-thia-1- azabicyclooct-2-ene-2-carboxylic acid
⚫	\| verifiedrevid = ~~437200211~~
		⚫	\| image = Cefmatilen.svg
⚫	\| IUPAC_name = (6''R'',7''R'')-7-{amino}-8-oxo-3-{sulfanyl}-5-thia-1- azabicyclooct-2-ene-2-carboxylic acid
		⚫	\| width = 280
⚫	\| image = Cefmatilen.svg

⚫	\| width = 280
			<!--Clinical data-->
⚫	\| CAS_number = 140128-74-1
			\| tradename =
⚫	\| CAS_supplemental = <br/>{{CAS\|154776-45-1}} (] · ])
		⚫	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	\| ATC_prefix = none
		⚫	\| pregnancy_US = <!-- A / B / C / D / X -->
⚫	\| ATC_suffix =
		⚫	\| pregnancy_category =
⚫	\| PubChem = 9690121
		⚫	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
		⚫	\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
		⚫	\| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
		⚫	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
		⚫	\| legal_status =
		⚫	\| routes_of_administration = Oral

			<!--Pharmacokinetic data-->
		⚫	\| bioavailability =
		⚫	\| protein_bound =
		⚫	\| metabolism =
		⚫	\| elimination_half-life =
		⚫	\| excretion =

			<!--Identifiers-->
		⚫	\| CAS_number_Ref = {{cascite\|correct\|??}}
		⚫	\| CAS_number = 140128-74-1
		⚫	\| CAS_supplemental = <br />{{CAS\|154776-45-1}} (] · ])
		⚫	\| ATC_prefix = none
		⚫	\| ATC_suffix =
		⚫	\| PubChem = 9690121
	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}		\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
	\| DrugBank =		\| DrugBank =
			\| ChEMBL = 2104438
⚫	\| C=15 \|H=14 \|N=8 \|O=5 \|S=4
		⚫	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| molecular_weight = 514.582 g/mol
⚫	\| smiles = C1C(=C(N2(S1)(C2=O)NC(=O)/C(=N\O)/C3=CSC(=N3)N)C(=O)O)SCSC4=NNN=C4
⚫	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| ChemSpiderID = 4912110		\| ChemSpiderID = 4912110
	\| ~~StdInChIKey_Ref~~ = {{~~stdinchicite~~\|correct\|~~chemspider~~}}		\| UNII_Ref = {{fdacite\|correct\|FDA}}
		⚫	\| UNII = T750UM24H8

			<!--Chemical data-->
		⚫	\| C=15 \| H=14 \| N=8 \| O=5 \| S=4
		⚫	\| smiles = C1C(=C(N2(S1)(C2=O)NC(=O)/C(=N\O)/C3=CSC(=N3)N)C(=O)O)SCSC4=NNN=C4
		⚫	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}
		⚫	\| StdInChI = 1S/C15H14N8O5S4/c16-15-18-5(2-30-15)8(21-28)11(24)19-9-12(25)23-10(14(26)27)6(3-29-13(9)23)31-4-32-7-1-17-22-20-7/h1-2,9,13,28H,3-4H2,(H2,16,18)(H,19,24)(H,26,27)(H,17,20,22)/b21-8-/t9-,13-/m1/s1
			\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChIKey = UEQVTKSAEXANEZ-YCRCPZNHSA-N		\| StdInChIKey = UEQVTKSAEXANEZ-YCRCPZNHSA-N
⚫	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}
⚫	\| StdInChI=1S/C15H14N8O5S4/c16-15-18-5(2-30-15)8(21-28)11(24)19-9-12(25)23-10(14(26)27)6(3-29-13(9)23)31-4-32-7-1-17-22-20-7/h1-2,9,13,28H,3-4H2,(H2,16,18)(H,19,24)(H,26,27)(H,17,20,22)/b21-8-/t9-,13-/m1/s1
⚫	\| bioavailability =
⚫	\| protein_bound =
⚫	\| metabolism =
⚫	\| elimination_half-life =
⚫	\| excretion =
⚫	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	\| pregnancy_US = <!-- A / B / C / D / X -->
⚫	\| pregnancy_category=
⚫	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫	\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫	\| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫	\| legal_status =
⚫	\| routes_of_administration = Oral
	}}		}}
	'''Cefmatilen''' (], codenamed '''S-1090''') is an orally-active ] antibiotic. It was developed in Japan and first described in 1992.<ref name=Tsuji/>		'''Cefmatilen''' (], codenamed '''S-1090''') is an orally-active ] antibiotic. It was developed in Japan and first described in 1992.<ref name=Tsuji/>

	''In vitro'', cefmatilen is highly active against a variety of ] and ] ], including '']'' and '']''.<ref name=Tsuji>{{cite journal \|~~author~~=Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K \|title=In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin \|journal=Antimicrob Agents Chemother \|volume=39 \|issue=11 \|pages=2544–51 \|~~year~~=1995 ~~\|month=November~~ \|pmid=8585742 \|pmc=162981 \|doi= ~~\|url=http:/~~/aac.~~asm~~.~~org/cgi/pmidlookup?view~~=~~long&pmid=8585742~~}}</ref>		''In vitro'', cefmatilen is highly active against a variety of ] and ] ], including '']'' and '']''.<ref name=Tsuji>{{cite journal \|vauthors=Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K \|title=In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin \|journal=Antimicrob Agents Chemother \|volume=39 \|issue=11 \|pages=2544–51 \|date=November 1995 \|pmid=8585742 \|pmc=162981 \|doi= 10.1128/aac.39.11.2544\|url=}}</ref>

	==References==		==References==
	<references/>		<references />

	==Further reading==		==Further reading==
	*{{cite journal \|author=Cazzola M \|title=Novel oral cephalosporins \|journal=Expert Opin Investig Drugs \|volume=9 \|issue=2 \|pages=237–46 \|~~year~~=2000 ~~\|month=February~~ \|pmid=11060674 \|doi=10.1517/13543784.9.2.237}}		* {{cite journal \|author=Cazzola M \|title=Novel oral cephalosporins \|journal=Expert Opin Investig Drugs \|volume=9 \|issue=2 \|pages=237–46 \|date=February 2000 \|pmid=11060674 \|doi=10.1517/13543784.9.2.237\|s2cid=45932120 }}
	{{-}}		{{Clear}}
	{{CephalosporinAntiBiotics}}		{{CephalosporinAntiBiotics}}

⚫	{{antibiotic-stub}}

	]		]
	]		]
	]		]
	]		]


		⚫	{{antibiotic-stub}}

Latest revision as of 22:16, 29 January 2023

Chemical compound Pharmaceutical compound

Cefmatilen
Clinical data

Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name (6R,7R)-7-{amino}-8-oxo-3-{sulfanyl}-5-thia-1- azabicyclooct-2-ene-2-carboxylic acid
CAS Number	140128-74-1 154776-45-1 (HCl · H₂O)
PubChem CID	9690121
ChemSpider	4912110
UNII	T750UM24H8
ChEMBL	ChEMBL2104438
CompTox Dashboard (EPA)	DTXSID50161236
Chemical and physical data
Formula	C₁₅H₁₄N₈O₅S₄
Molar mass	514.57 g·mol
3D model (JSmol)	Interactive image
SMILES C1C(=C(N2(S1)(C2=O)NC(=O)/C(=N\O)/C3=CSC(=N3)N)C(=O)O)SCSC4=NNN=C4
InChI InChI=1S/C15H14N8O5S4/c16-15-18-5(2-30-15)8(21-28)11(24)19-9-12(25)23-10(14(26)27)6(3-29-13(9)23)31-4-32-7-1-17-22-20-7/h1-2,9,13,28H,3-4H2,(H2,16,18)(H,19,24)(H,26,27)(H,17,20,22)/b21-8-/t9-,13-/m1/s1 Key:UEQVTKSAEXANEZ-YCRCPZNHSA-N
(verify)

Cefmatilen (INN, codenamed S-1090) is an orally-active cephalosporin antibiotic. It was developed in Japan and first described in 1992.

In vitro, cefmatilen is highly active against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.

References

^ Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K (November 1995). "In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin". Antimicrob Agents Chemother. 39 (11): 2544–51. doi:10.1128/aac.39.11.2544. PMC 162981. PMID 8585742.

β-lactamase sensitive (1st generation)	Benzylpenicillin (G) Benzathine benzylpenicillin Procaine benzylpenicillin Phenoxymethylpenicillin (V) Propicillin Pheneticillin Azidocillin Clometocillin Penamecillin
β-lactamase resistant (2nd generation)	Cloxacillin (Dicloxacillin Flucloxacillin) Oxacillin Nafcillin Methicillin

Extended
spectrum

Aminopenicillins (3rd generation)	Amoxicillin Ampicillin (Pivampicillin Hetacillin Bacampicillin Lenampicillin Metampicillin Talampicillin) Epicillin
Carboxypenicillins (4th generation)	Ticarcillin Carbenicillin / Carindacillin Temocillin
Ureidopenicillins (4th generation)	Piperacillin Azlocillin Mezlocillin
Other	Mecillinam (Pivmecillinam) Sulbenicillin

Carbapenems / Penems

Cephems
Cephalosporins
Cephamycins
Carbacephems

1st generation	Cefazolin Cefalexin Cefadroxil Cefapirin Cefazedone Cefazaflur Cefradine Cefroxadine Ceftezole Cefaloglycin Cefacetrile Cefalonium Cefaloridine Cefalotin Cefatrizine
2nd generation	Cefaclor Cefprozil Cefuroxime Cefuroxime axetil Cefamandole Cefonicid Ceforanide Cefuzonam Cephamycin (Cefoxitin Cefotetan Cefminox Cefbuperazone Cefmetazole) Carbacephem (Loracarbef)
3rd generation	Cefixime Ceftriaxone Cefotaxime Antipseudomonal (Ceftazidime Cefoperazone) Cefdinir Cefcapene Cefdaloxime Ceftizoxime Cefmenoxime Cefpiramide Cefpodoxime Ceftibuten Cefditoren Cefotiam Cefetamet Cefodizime Cefpimizole Cefsulodin Cefteram Ceftiolene Oxacephem (Flomoxef Latamoxef)
4th generation	Cefepime Cefozopran Cefpirome Cefquinome
5th generation	Ceftaroline fosamil Ceftolozane Ceftobiprole
Siderophore	Cefiderocol
Veterinary	Ceftiofur Cefquinome Cefovecin

Monobactams

β-lactamase inhibitors

Combinations

Polypeptides

Lipopeptides	Insert into bacterial cell wall causing perforation and depolarization: Daptomycin Surfactin
Other	Inhibits PG elongation and crosslinking: Ramoplanin

Intracellular

Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
DADAL/AR inhibitors (Cycloserine)
bactoprenol inhibitors (Bacitracin)

Other

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:

Latest revision as of 22:16, 29 January 2023

References

Further reading